Hepatitis C antivirals: risk of severe bradycardia

Clinically significant arrhythmias have been reported when Harvoni (sofosbuvir + ledipasvir) or Daklinza (daclatasvir) in combination with Sovaldi (sofosbuvir) are given concomitantly with amiodarone, the MHRA has warned.

In amiodarone-treated patients bradycardia was observed within 24 hours of initiating hepatitis C treatment in some cases and as long as 12 days after in others. | SCIENCE PHOTO LIBRARY
In amiodarone-treated patients bradycardia was observed within 24 hours of initiating hepatitis C treatment in some cases and as long as 12 days after in others. | SCIENCE PHOTO LIBRARY

Patients with cardiac rhythm disorders taking the fixed-dose combination of sofosbuvir and ledipasvir, or sofosbuvir in combination with daclatasvir, should be closely monitored if they are receiving concomitant amiodarone, especially during the first few weeks of concomitant treatment. Continuous monitoring for 48 hours is required for patients at high risk of bradyarrhythmia.

Further information
MHRA Drug Safety Update

Owing to the long half-life of amiodarone, patients who have discontinued the antiarrhythmic within the past few months and are to be initiated on either of the above antiviral combinations should be monitored.

Amiodarone should only be initiated in patients taking these antiviral combinations if patients are unable to tolerate or cannot take other antiarrhythmics. Healthcare professionals should advise patients to urgently report signs and symptoms of bradycardia and cardiac block including:
  • shortness of breath
  • light-headedness
  • palpitations
  • fainting

 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases